Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …

Acute myeloid leukemia (AML) is a highly heterogeneous malignancy of the blood and bone
marrow, characterized by clonal expansion of myeloid stem and progenitor cells and rapid …

Background Acute myeloid leukemia (AML) is a hematological malignancy that remains a
therapeutic challenge due to the high incidence of disease relapse. To better understand …

Acute myeloid leukemia (AML) and B-cell acute lymphocytic leukemia (B-ALL) are severe
blood malignancies affecting both adults and children. Chimeric antigen receptor (CAR) …

Background Acute myeloid leukaemia (AML) is a deadly disease characterised by the
uncontrolled proliferation of immature myeloid cells within the bone marrow. Altered …

Increased bone marrow (BM) homing of NK cells is associated with positive outcome in
patients with acute myeloid leukemia (AML) treated within adoptive NK cell transfer trials …

In acute myeloid leukemia (AML), malignant stem cells hijack the normal bone marrow niche
where they are largely protected from the current therapeutic approaches. Thus, eradicating …

Acute myeloid leukemia (AML) is a prevalent hematological malignancy that exhibits a wide
array of molecular abnormalities. Although traditional treatment modalities such as …

Background. Histone deacetylase 3 (HDAC3) plays an important role in the development
and progression of a variety of cancers, but its regulatory mechanism in acute myeloid …

Introduction Acute myeloid leukemia (AML) is a highly heterogeneous malignancy caused
by various genetic alterations and characterized by the accumulation of immature myeloid …